Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2017 Summary According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis. The report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Crohn's Disease (Regional Enteritis), Kidney Transplant Rejection, Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Rheumatoid Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Graves Diseases, Heart Transplant Rejection, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hyperthyroidism, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Multiple Sclerosis, Myasthenia Gravis, Osteosarcoma, Pancreatic Islet Transplant Rejection, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects - The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Overview 8 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Development 9 Products under Development by Stage of Development 9 Products under Development by Therapy Area 10 Products under Development by Indication 11 Products under Development by Companies 14 Products under Development by Universities/Institutes 19 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Therapeutics Assessment 21 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Companies Involved in Therapeutics Development 27 AbbVie Inc 27 Apexigen Inc 28 Apogenix GmbH 28 Boehringer Ingelheim GmbH 29 Bristol-Myers Squibb Company 29 Celldex Therapeutics Inc 30 Denceptor Therapeutics Ltd 30 F. Hoffmann-La Roche Ltd 31 Johnson & Johnson 32 Kyowa Hakko Kirin Co Ltd 33 Novartis AG 34 Seattle Genetics Inc 35 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Drug Profiles 36 2C-10 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ABBV-428 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 APG-1233 - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 APX-005M - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 BI-655064 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Bispecific Monoclonal Antibody to Agonize CD40 for Oncology - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 bleselumab - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 BMS-986090 - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 CDX-1140 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 CFZ-533 - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 DNP-005 - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 emactuzumab + RG-7876 - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 FFP-104 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 JNJ-7107 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 KGYY-15 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Monoclonal Antibodies to Agonize CD40 and FCGR2B for B-cell Lymphoma and Melanoma - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Monoclonal Antibody Conjugate to Target CD40 for Pancreatic Cancer - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 RG-7876 - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 RG-7876 + vanucizumab - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 SEA-CD40 - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Dormant Products 63 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Discontinued Products 65 Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Product Development Milestones 66 Featured News & Press Releases 66 Jul 17, 2017: Apexigen Announces First Patient Dosed in Phase 1b/2 Clinical Trial of APX005M in Combination with Opdivo (nivolumab) in Advanced Solid Tumors 66 May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ADC-1013 66 Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ADC-1013 at PEGS conference in Boston, May 4 67 Apr 03, 2017: Phase I Clinical Trial Completes Using Cell Line Expertise at Cobra Biologics 67 Mar 23, 2017: Alligator announces completion of first phase I study with CD40 agonistic immuno-oncology antibody ADC-1013 68 Mar 21, 2017: Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda) Opens for Metastatic Melanoma Patients 68 Dec 05, 2016: Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology Annual Meeting 69 Nov 14, 2016: Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody 69 Oct 12, 2016: Alligator Bioscience informs that dosing has started in a second clinical phase I study with the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 70 Apr 22, 2016: Alligator Bioscience Recieves First Milestone Payment for ADC-1013 70 Apr 18, 2016: Seattle Genetics Highlights Data on SEA-CD40 at the American Association for Cancer Research Annual Meeting 71 Apr 13, 2016: Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences 71 Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn's Disease with anti-CD40 Monoclonal Antibody 72 Nov 17, 2015: Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe 72 Nov 06, 2015: Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting 73 Appendix 74 Methodology 74 Coverage 74 Secondary Research 74 Primary Research 74 Expert Panel Validation 74 Contact Us 74 Disclaimer 75
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9 Number of Products under Development by Therapy Areas, H2 2017 10 Number of Products under Development by Indications, H2 2017 11 Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12 Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13 Number of Products under Development by Companies, H2 2017 14 Products under Development by Companies, H2 2017 15 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18 Number of Products under Investigation by Universities/Institutes, H2 2017 19 Products under Investigation by Universities/Institutes, H2 2017 20 Number of Products by Stage and Mechanism of Actions, H2 2017 22 Number of Products by Stage and Route of Administration, H2 2017 24 Number of Products by Stage and Molecule Type, H2 2017 26 Pipeline by AbbVie Inc, H2 2017 27 Pipeline by Apexigen Inc, H2 2017 28 Pipeline by Apogenix GmbH, H2 2017 28 Pipeline by Boehringer Ingelheim GmbH, H2 2017 29 Pipeline by Bristol-Myers Squibb Company, H2 2017 29 Pipeline by Celldex Therapeutics Inc, H2 2017 30 Pipeline by Denceptor Therapeutics Ltd, H2 2017 30 Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 31 Pipeline by Johnson & Johnson, H2 2017 32 Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 33 Pipeline by Novartis AG, H2 2017 34 Pipeline by Seattle Genetics Inc, H2 2017 35 Dormant Products, H2 2017 63 Dormant Products, H2 2017 (Contd..1), H2 2017 64 Discontinued Products, H2 2017 65
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
